Janssen Research & Development, LLC clinical trials

A subsidiary of Johnson & Johnson

The registry lists 929 studies whose lead sponsor is Janssen Research & Development, LLC. 76 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 20, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 929. List all 929 → · All Johnson & Johnson studies →

• A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's DiseaseRecruitingNCT07577843Phase 3

  Sponsor listed in the registry: Janssen Research & Development, LLC

• A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative ColitisRecruitingNCT07577856Phase 3

  Sponsor listed in the registry: Janssen Research & Development, LLC

• A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not PlannedRecruitingNCT07665450Phase 3

  Sponsor listed in the registry: Janssen Research & Development, LLC

• A Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA TherapeuticallyRecruitingNCT07654751Phase 4

  Sponsor listed in the registry: Janssen Research & Development, LLC

• A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple MyelomaRecruitingNCT07589634Phase 2

  Sponsor listed in the registry: Janssen Research & Development, LLC

• A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive DisorderRecruitingNCT07573176Phase 3

  Sponsor listed in the registry: Janssen Research & Development, LLC

• A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)RecruitingNCT06635148Phase 2/3

  Sponsor listed in the registry: Janssen Research & Development, LLC

• A Study of JNJ-95437446 in Participants With Advanced-Stage Solid TumorsRecruitingNCT07107230Phase 1

  Sponsor listed in the registry: Janssen Research & Development, LLC

• A Study to Assess Nipocalimab Concentrations in Breast Milk of Healthy Lactating WomenRecruitingNCT07669077Phase 1

  Sponsor listed in the registry: Janssen Research & Development, LLC

• A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate CancerRecruitingNCT06095089Phase 1

  Sponsor listed in the registry: Janssen Research & Development, LLC

• A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) AmyloidosisRecruitingNCT05652335Phase 1

  Sponsor listed in the registry: Janssen Research & Development, LLC

• A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder CancerRecruitingNCT06919965Phase 3

  Sponsor listed in the registry: Janssen Research & Development, LLC

• A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung CancerRecruitingNCT05498428Phase 2

  Sponsor listed in the registry: Janssen Research & Development, LLC

• A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With SchizophreniaRecruitingNCT07615426Phase 1

  Sponsor listed in the registry: Janssen Research & Development, LLC

• A Study of JNJ-89862175 for Treatment of Advanced Solid TumorsRecruitingNCT07223125Phase 1

  Sponsor listed in the registry: Janssen Research & Development, LLC

• A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's DiseaseRecruitingNCT05923073Phase 3

  Sponsor listed in the registry: Janssen Research & Development, LLC

• A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder CancerRecruitingNCT06319820Phase 3

  Sponsor listed in the registry: Janssen Research & Development, LLC

• A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck CancerRecruitingNCT06385080Phase 1/2

  Sponsor listed in the registry: Janssen Research & Development, LLC

• A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple MyelomaRecruitingNCT06768489Phase 1

  Sponsor listed in the registry: Janssen Research & Development, LLC

• A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)RecruitingNCT04811560Phase 1/2

  Sponsor listed in the registry: Janssen Research & Development, LLC

• A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)RecruitingNCT06667076Phase 2

  Sponsor listed in the registry: Janssen Research & Development, LLC

• A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received ChemotherapyRecruitingNCT06750094Phase 3

  Sponsor listed in the registry: Janssen Research & Development, LLC

• A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative NeoplasmsRecruitingNCT06150157Phase 1

  Sponsor listed in the registry: Janssen Research & Development, LLC

• A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal CancerRecruitingNCT06662786Phase 3

  Sponsor listed in the registry: Janssen Research & Development, LLC

• A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple MyelomaRecruitingNCT05552222Phase 3

  Sponsor listed in the registry: Janssen Research & Development, LLC

• A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic ArthritisRecruitingNCT06807424Phase 3

  Sponsor listed in the registry: Janssen Research & Development, LLC

• A Long-term Study for Participants Previously Treated With Ciltacabtagene AutoleucelRecruitingNCT05201781Phase 4

  Sponsor listed in the registry: Janssen Research & Development, LLC

• A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal CancerRecruitingNCT05379595Phase 1/2

  Sponsor listed in the registry: Janssen Research & Development, LLC

• A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)RecruitingNCT05912517Phase 3

  Sponsor listed in the registry: Janssen Research & Development, LLC

• A Study of JNJ-89402638 for Metastatic Colorectal and Gastric CancersRecruitingNCT06663319Phase 1

  Sponsor listed in the registry: Janssen Research & Development, LLC

• Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate CancerRecruitingNCT06800313Phase 1/2

  Sponsor listed in the registry: Janssen Research & Development, LLC

• Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)RecruitingNCT05327114Phase 2/3

  Sponsor listed in the registry: Janssen Research & Development, LLC

• A Study of JNJ-87890387 for Advanced Solid TumorsRecruitingNCT06178614Phase 1

  Sponsor listed in the registry: Janssen Research & Development, LLC

• Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia SymptomsRecruitingNCT06559306Phase 3

  Sponsor listed in the registry: Janssen Research & Development, LLC

• A Long-term Extension (LTE) Study of Guselkumab in Pediatric ParticipantsRecruitingNCT06663332Phase 3

  Sponsor listed in the registry: Janssen Research & Development, LLC

• A Study of Talquetamab in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT04634552Phase 2

  Sponsor listed in the registry: Janssen Research & Development, LLC

• A Rollover Study for Continued Study Treatment and Ongoing Safety MonitoringEnrolling by invitationNCT06788509Phase 1

  Sponsor listed in the registry: Janssen Research & Development, LLC

• A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)RecruitingNCT06852222Phase 3

  Sponsor listed in the registry: Janssen Research & Development, LLC

• A Study to Evaluate Preventive Treatments for GPRC5D-related Oral EventsRecruitingNCT06500884Phase 2

  Sponsor listed in the registry: Janssen Research & Development, LLC

• A Study of Nipocalimab in Reducing the Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)RecruitingNCT06449651Phase 3

  Sponsor listed in the registry: Janssen Research & Development, LLC

• A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate CancerRecruitingNCT05818683Phase 1

  Sponsor listed in the registry: Janssen Research & Development, LLC

• A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)RecruitingNCT06533098Phase 3

  Sponsor listed in the registry: Janssen Research & Development, LLC

• A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate CancerRecruitingNCT07082920Phase 1

  Sponsor listed in the registry: Janssen Research & Development, LLC

• A Real-world Study of Ibrutinib and Venetoclax (I+V) First-Line Treatment Given for Fixed-duration of Time in Participants With Chronic Lymphocytic LeukemiaRecruitingNCT07602088

  Sponsor listed in the registry: Janssen Research & Development, LLC

• A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate CancerRecruitingNCT07319871Phase 1

  Sponsor listed in the registry: Janssen Research & Development, LLC

• A Study of Persistence to Guselkumab Treatment in Participants With Moderate-to-Severe Plaque Psoriasis in RomaniaRecruitingNCT07582783

  Sponsor listed in the registry: Janssen Research & Development, LLC

• A Study to Evaluate Efficacy and Safety of Ciltacabtagene AutoleucelRecruitingNCT07149857Phase 2

  Sponsor listed in the registry: Janssen Research & Development, LLC

• A Study of JNJ-95804306 for Relapsed or Refractory Hematological MalignanciesRecruitingNCT07572006Phase 1

  Sponsor listed in the registry: Janssen Research & Development, LLC

• A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate CancerRecruitingNCT07225946Phase 3

  Sponsor listed in the registry: Janssen Research & Development, LLC

• Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia GravisRecruitingNCT07217587Phase 3

  Sponsor listed in the registry: Janssen Research & Development, LLC